NCT06796062View on ClinicalTrials.gov

Psilocybin for Opioid Use Disorder (OUD)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions
Opioid Use Disorder
Interventions
DRUG

Psilocybin

One capsule (1 mg, 20 mg, or 30 mg) administered once orally

Trial Locations (5)

10016

NYU Langone Health, New York

10457

VIP Community Services, Inc, The Bronx

11206

Start Treatment & Recovery Centers, Brooklyn

87102

Duke City Recovery Toolbox, Albuquerque

87106

University of New Mexico, Albuquerque

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

NYU Langone Health

OTHER